Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tandospirone Citrate in Generalized Anxiety Disorder
NCT01614041Phase 4Completed
- Sponsor
- Sumitomo Pharma
- Start
- Jan 2012
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tandospirone in generalized anxiety disorder (GAD) (2 arms), sponsored by Sumitomo Pharma. Primary endpoint: Percentage of patients with HAMA change >= 50% at 6 weeks. Started Jan 2012; status: completed.
02
Drugs
tandospirone
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT01614041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01614041.